Wuhan Keqian Biology Co.,Ltd (SHA:688526)
12.68
-0.29 (-2.24%)
Sep 2, 2026, 3:00 PM CST
SHA:688526 Revenue
Wuhan Keqian Biology Co.,Ltd had revenue of 146.29M CNY in the quarter ending June 30, 2026, a decrease of -39.57%. This brings the company's revenue in the last twelve months to 836.28M, down -18.71% year-over-year. In the year 2025, Wuhan Keqian Biology Co.,Ltd had annual revenue of 949.74M with 0.83% growth.
Revenue (ttm)
836.28M
Revenue Growth
-18.71%
P/S Ratio
7.19
Revenue / Employee
880.29K
Employees
950
Market Cap
6.02B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 949.74M | 7.82M | 0.83% |
| Dec 31, 2024 | 941.92M | -122.15M | -11.48% |
| Dec 31, 2023 | 1.06B | 62.81M | 6.27% |
| Dec 31, 2022 | 1.00B | -101.75M | -9.22% |
| Dec 31, 2021 | 1.10B | 259.79M | 30.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Youcare Pharmaceutical Group | 2.46B |
| Novogene | 2.28B |
| Chengdu Kanghua Biological Products | 1.22B |
| Shenzhen Weiguang Biological Products | 1.20B |
| Boji Medical Technology | 961.34M |
| Zhejiang Ausun Pharmaceutical | 778.50M |
| Jiangsu Aidea Pharmaceutical Group | 722.54M |
| PharmaResources (Shanghai) | 700.02M |